Devidas, Meenakshi

Research ProfessorFACULTY_DevidasMeenakshi

  • Office:  6011 NW 1st Place
  • Phone:  352-273-0551
  • Fax:  352-392-8162
  • Email:

Department of Biostatistics
Children’s Oncology Group
Department of Biostatistics
6011 NW 1st Place
Gainesville, FL 32607-2025


  • PhD, University of Memphis, Memphis, TN (Major: Applied Statistics, Minor: Computer Science)
  • MS, University of Memphis, Memphis, TN (Major: Applied Statistics)
  • MBA, Bangalore University, Bangalore, India (Major: Marketing Management)
  • BS, Bangalore University, Bangalore, India (Majors: Mathematics, Physics, and Chemistry)


Professional Biography

Meenakshi Devidas is PI of the U10 grant from the National Cancer Institute (NCI) supporting the Children’s Oncology Group Statistics and Data Center (COG SDC). The COG is a NCI sponsored cooperative group, and is the world’s largest organization devoted exclusively to childhood and adolescent cancer research. The COG unites more than 8,000 experts in childhood cancer at more than 200 leading children’s hospitals, universities, and cancer centers across North America, Australia, New Zealand and Europe, in the fight against childhood cancer. Dr. Devidas is the Lead Statistician for the disease area of Acute Lymphoblastic Leukemia (ALL) and resource statistician for Bone tumors (Ewing Sarcoma and Osteosarcoma). In this role, she is responsible for reviewing concept proposals, trial design, sample size calculations, and developing / implementing safety and efficacy monitoring rules for new clinical trials in these disease areas. She is co-investigator on several NIH grants looking at prognostic significance of minimal residual disease and the biology of ALL in children. Her methodological research has focused on statistical issues related to the design and conduct of clinical trials, and the modeling of dose-response curves. Designing randomized comparative trials in disease areas with very low annual accruals is problematic. Dr. Devidas developed methodology for sample size estimations in Phase II and pilot trials where data from a completed or ongoing study (historical controls) may be effectively used in the design and analysis of a new comparative study. Current research includes efficient two-stage designs for Phase II trials which need to be monitored for insufficient activity (low response rates) and/or excessive early disease progression rates.


  • Clinical Trials Design
  • Statistical Applications to Clinical Trials
  • Survival Analysis
  • Group Sequential Methods
  • Generalized Linear Models
  • Dose-Response Modeling